Innocare (09969) rose more than 11% again, with the stock up 11.08% to HK$13.15 at the time of writing, and a turnover of HK$155 million. The company issued a positive profit alert, forecasting revenue of RMB2.37 billion for 2025, a year-on-year increase of approximately 134%. It also expects to achieve its first-ever net profit attributable to shareholders in 2025, reaching around RMB630 million. The performance growth is primarily driven by sustained rapid expansion in pharmaceutical revenue and increased business development income. Throughout 2025, the company advanced its globalization strategy, completing two business development transactions. Ping An Securities noted that the core product, orelabrutinib, is steadily gaining market share, with comprehensive development across hematologic malignancies, autoimmune diseases, and solid tumors. The company is also actively pursuing external collaborations, having secured two out-licensing deals in 2025, which include upfront and future milestone payments. Revenue forecasts for 2025–2027 have been raised to RMB2.371 billion, RMB2.575 billion, and RMB2.732 billion, respectively, with growth rates of 134.9%, 8.6%, and 6.1% over the period. The "recommend" rating has been maintained.